InsiderTradr

CSL Limited (CSLLY)

OTC Markets OTCQX · USD · Healthcare · Biotechnology

$34.58 (+1.23%) as of

Key statistics

Market cap
66.38B
Forward P/E
20.56
EPS (TTM)
-1.34
Dividend yield
2.08%
52-week range
16.01 – 35.64
Beta
0.08
Revenue (TTM)
15.8B
Profit margin
-16.33%
Analyst target
$35.50
Volume
100.00

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Melbourne, VIC, Australia
Employees
29,000

csl.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks